Aligos Therapeutics (ALGS) Stock Forecast, Price Target & Predictions
ALGS Stock Forecast
Aligos Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a -79.15% downside from ALGS’s last price of $14.39) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.
ALGS Price Target
The average price target for Aligos Therapeutics (ALGS) is $3.00 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential -79.15% downside from ALGS's last price of $14.39.
ALGS Analyst Ratings
According to 13 Wall Street analysts, Aligos Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for ALGS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (30.77%), 8 'Hold' (61.54%), 1 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).
Aligos Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 06, 2023 | - | Piper Sandler | $3.00 | $1.22 | 146.91% | -79.15% |
| Jan 06, 2023 | - | Jefferies | $3.00 | $0.99 | 203.03% | -79.15% |
The latest Aligos Therapeutics stock forecast, released on Jan 06, 2023 by Piper Sandler company, set a price target of $3.00, which represents a 146.91% increase from the stock price at the time of the forecast ($1.22), and a -79.15% decrease from ALGS last price ($14.39).
Aligos Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $14.39 | $14.39 | $14.39 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Aligos Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aligos Therapeutics's last price of $14.39. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 19, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Jul 19, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jan 06, 2023 | Morgan Stanley | - | Underweight | Downgrade |
| Jan 06, 2023 | Barclays | - | Equal-Weight | Downgrade |
| Jan 06, 2023 | Wedbush | - | Neutral | Downgrade |
| Jan 06, 2023 | Cowen & Co. | - | Market Perform | Downgrade |
| Jan 06, 2023 | J.P. Morgan | - | Neutral | Downgrade |
| Jan 06, 2023 | Piper Sandler | Overweight | Neutral | Downgrade |
Aligos Therapeutics's last stock rating was published by Piper Sandler on Sep 12, 2024. The company gave ALGS a "Overweight" rating, the same as its previous rate.
Aligos Therapeutics Financial Forecast
Aligos Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $3.54M | $4.11M | $2.57M | $910.00K |
| Avg Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $2.18M | $1.07M |
| High Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $2.62M | $1.29M |
| Low Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $1.75M | $857.42K |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | - | - | - | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.65% | 5.47% | 1.18% | 0.85% |
Aligos Therapeutics's average Quarter revenue forecast for Sep 23 based on 0 analysts is $2.50M, with a low forecast of $2.50M, and a high forecast of $2.50M. ALGS's average Quarter revenue forecast represents a -29.32% decrease compared to the company's last Quarter revenue of $3.54M (Dec 22).
Aligos Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | - | - | - | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $-19.07M | $-22.68M | $-18.04M | $-34.57M | $-26.76M |
| Avg Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-37.36M | $-29.30M | $-31.51M |
| High Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-29.89M | $-23.44M | $-25.21M |
| Low Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-44.83M | $-35.15M | $-37.82M |
| Surprise % | - | - | - | - | - | - | - | - | 38.14% | 52.75% | 0.48% | 1.18% | 0.85% |
undefined analysts predict ALGS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aligos Therapeutics's previous annual EBITDA (undefined) of $NaN.
Aligos Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | - | - | - | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $-18.04M | $-21.89M | $-18.62M | $-35.62M | $-27.67M |
| Avg Forecast | $-149.25M | $-137.39M | $-129.93M | $-125.61M | $-108.11M | $-166.15M | $-25.06M | $-43.86M | $-74.41M | $-78.32M | $-38.63M | $-30.25M | $-32.59M |
| High Forecast | $-149.25M | $-137.39M | $-129.93M | $-125.61M | $-108.11M | $34.78M | $-25.06M | $-17.87M | $-74.41M | $-78.32M | $-30.91M | $-24.20M | $-26.08M |
| Low Forecast | $-149.25M | $-137.39M | $-129.93M | $-125.61M | $-108.11M | $-340.03M | $-25.06M | $-69.85M | $-74.41M | $-78.32M | $-46.36M | $-36.30M | $-39.11M |
| Surprise % | - | - | - | - | - | - | - | - | 0.24% | 0.28% | 0.48% | 1.18% | 0.85% |
Aligos Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALGS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Aligos Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | - | - | - | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $6.44M | $7.12M | $5.26M | $6.45M | $5.78M |
| Avg Forecast | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $2.58M | $3.90M | $6.09M | $5.23M | $1.83M | $5.32M | $2.61M |
| High Forecast | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $2.58M | $3.90M | $6.09M | $5.23M | $1.83M | $6.38M | $3.13M |
| Low Forecast | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $811.48K | $2.58M | $3.90M | $6.09M | $5.23M | $1.83M | $4.25M | $2.09M |
| Surprise % | - | - | - | - | - | - | - | - | 1.06% | 1.36% | 2.88% | 1.21% | 2.22% |
Aligos Therapeutics's average Quarter SG&A projection for Dec 23 is $3.90M, based on 1 Wall Street analysts, with a range of $3.90M to $3.90M. The forecast indicates a -39.54% fall compared to ALGS last annual SG&A of $6.44M (Sep 23).
Aligos Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | - | - | - | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | $-0.41 | $-0.51 | $-0.44 | $-0.84 | $-0.74 |
| Avg Forecast | $-23.82 | $-21.93 | $-20.74 | $-20.05 | $-17.25 | $-26.52 | $-4.00 | $-7.00 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
| High Forecast | $-23.82 | $-21.93 | $-20.74 | $-20.05 | $-17.25 | $5.55 | $-4.00 | $-2.85 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
| Low Forecast | $-23.82 | $-21.93 | $-20.74 | $-20.05 | $-17.25 | $-54.27 | $-4.00 | $-11.15 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
| Surprise % | - | - | - | - | - | - | - | - | 0.03% | 0.04% | 0.03% | 0.05% | 0.03% |
According to undefined Wall Street analysts, Aligos Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALGS previous annual EPS of $NaN (undefined).
Aligos Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.33 | $10.00 | 651.88% | Buy |
| CTMX | CytomX Therapeutics | $1.21 | $5.77 | 376.86% | Buy |
| ACHL | Achilles Therapeutics | $0.71 | $2.00 | 181.69% | Buy |
| NUVB | Nuvation Bio | $3.07 | $6.75 | 119.87% | Buy |
| NXTC | NextCure | $1.38 | $3.00 | 117.39% | Buy |
| TIL | Instil Bio | $64.79 | $78.25 | 20.77% | Hold |
| ALGS | Aligos Therapeutics | $14.39 | $3.00 | -79.15% | Hold |
ALGS Forecast FAQ
Is Aligos Therapeutics a good buy?
No, according to 13 Wall Street analysts, Aligos Therapeutics (ALGS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 30.77% of ALGS's total ratings.
What is ALGS's price target?
Aligos Therapeutics (ALGS) average price target is $3 with a range of $3 to $3, implying a -79.15% from its last price of $14.39. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aligos Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ALGS stock, the company can go down by -79.15% (from the last price of $14.39 to the average price target of $3), down by -79.15% based on the highest stock price target, and down by -79.15% based on the lowest stock price target.
Can Aligos Therapeutics stock reach $20?
ALGS's average twelve months analyst stock price target of $3 does not support the claim that Aligos Therapeutics can reach $20 in the near future.
What are Aligos Therapeutics's analysts' financial forecasts?
Aligos Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.73M (high $1.73M, low $1.73M), average EBITDA is $-346K (high $-346K, low $-346K), average net income is $-299M (high $-98.396M, low $-473M), average SG&A $4.21M (high $4.21M, low $4.21M), and average EPS is $-47.77 (high $-15.703, low $-75.52). ALGS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.33M (high $1.33M, low $1.33M), average EBITDA is $-267K (high $-267K, low $-267K), average net income is $-542M (high $-542M, low $-542M), average SG&A $3.25M (high $3.25M, low $3.25M), and average EPS is $-86.53 (high $-86.53, low $-86.53).
Did the ALGS's actual financial results beat the analysts' financial forecasts?
Based on Aligos Therapeutics's last annual report (Dec 2022), the company's revenue was $13.91M, beating the average analysts forecast of $5.08M by 173.57%. Apple's EBITDA was $-97.58M, beating the average prediction of $-67.082M by 45.46%. The company's net income was $-96.046M, missing the average estimation of $-147M by -34.75%. Apple's SG&A was $26.41M, beating the average forecast of $12.38M by 113.40%. Lastly, the company's EPS was $-2.25, missing the average prediction of $-45.188 by -95.02%. In terms of the last quarterly report (Dec 2022), Aligos Therapeutics's revenue was $3.54M, beating the average analysts' forecast of $2.15M by 64.51%. The company's EBITDA was $-22.682M, beating the average prediction of $-430K by 5174.90%. Aligos Therapeutics's net income was $-21.886M, missing the average estimation of $-78.324M by -72.06%. The company's SG&A was $7.12M, beating the average forecast of $5.23M by 36.01%. Lastly, the company's EPS was $-0.51, missing the average prediction of $-12.5 by -95.92%